Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company’s infectious disease therapies, XACDURO ® (sulbactam/durlobactam...
IST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth Royalties portfolio generated $59.8 million in second...
Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive Company...
Agreement expands access to XACDURO ® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central...
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known...
Generated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year...
Barchart Research What to Expect from INVA Earnings INVA Generated May 5, 2026 Current Price $22.65 EPS Estimate $$0.43 Consensus Rating Moderate Buy Average Move 3.03% Innoviva's Royalty Foundation Meets...
Three low P/E small-cap stocks offer distinct catalysts and upside potential as investors look ahead to a broader market rally